key: cord-0793575-1ruexrd7
authors: De Francesco, Maria Antonia; Poiesi, Claudio; Gargiulo, Franco; Bonfanti, Carlo; Pollara, Patrizia; Fiorentini, Simona; Caccuri, Francesca; Carta, Valentina; Mangeri, Lucia; Pellizzeri, Simone; Rizzoni, Damiano; Malerba, Paolo; Salvetti, Massimo; Muiesan, Maria Lorenza; Alberici, Federico; Scolari, Francesco; Pilotto, Andrea; Padovani, Alessandro; Bezzi, Michela; Chiappini, Raffaella; Ricci, Chiara; Castellano, Maurizio; Berlendis, Marialma; Savio, Giulia; Montani, Giovanni; Ronconi, Maurizio; Bove, Sergio; Focà, Emanuele; Tomasoni, Lina; Castelli, Francesco; Rossini, Angelo; Inciardi, Riccardo; Metra, Marco; Caruso, Arnaldo
title: Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features
date: 2021-01-19
journal: J Infect
DOI: 10.1016/j.jinf.2021.01.009
sha: 4df2a4f537ccd3cd927a271791e6433ea046549d
doc_id: 793575
cord_uid: 1ruexrd7

nan

We read with great interest the recent article published by Lansbury et al. in this Journal. They found that only 7% of hospitalized COVID-19 patients had a bacterial co-infection, increasing to 14% in studies that only included ICU patients, a percentage very low when compared to bacterial coinfections associated with previous influenza pandemics 1 . The Authors underline that testing for co-infecting pathogens during the course of a pandemic is important but most of the studies they screened did not report on this.

Then, few works reported coinfection with atypical pathogens such as Mycoplasma pneumoniae [2] [3] [4] [5] [6] [7] and Chlamydia pneumoniae 8 , even if previous studies on severe coronavirus infections have shown a serological evidence among SARS patients that the incidence of acute or recent Chlamydia pneumoniae and Mycoplasma pneumoniae infection was about 30% and 9%, respectively 9 .

Here, we present a retrospective study with the aim to evaluate the prevalence of co-infections with atypical pathogens in SARS-CoV-2 infected patients compared to non-infected patients. Patients with SARS-CoV-2 and antibody positivity for Mycoplasma and/or Chlamydia had a higher median leukocyte count (median 6.6 [IQR, 3.6] x10 9 /L vs median 5.7 [IQR, 3.8] x10 9 /L, p=0.01) and a lower level of lymphocytes (71.9% vs 62%, p=0.003) (Table S1 ). An increased ALT serum level (29.1% vs 19.8%, p=0.02) and also a higher median serum level (median 33 [IQR, 31] U/L vs 26 [IQR, 26] U/L, p=0.02) was found in a higher percentage of patients with SARS-CoV-2 and antibody positivity for Mycoplasma and/or Chlamydia pneumoniae (Table S1) Table S2 ).

The proportions of critical COVID-19 patients with atypical pathogens coinfection were higher than those of patients infected only with SARS-CoV-2 (13.2% vs 5.9%, p=0.01). Furthermore, requirement and use of a nasal cannula, high flow oxygen support and non-invasive ventilation was significantly higher in co-infected patients than in only SARS-CoV-2 positive patients (18.1% vs 3.6%, p<0.0001; 45% vs 23.3%, p<0.0001; 14.7% vs 4.6%, p=0.001, respectively) (Table S2 ).

There were significantly more patients need mechanical ventilation support in SARS-CoV-2 and antibody positivity for Mycoplasma and/or Chlamydia pneumoniae than in the other group of patients (6.8% vs 2.5%, p=0.04) (Table S2) Patients with SARS-CoV-2 and antibody positivity for Mycoplasma and/or Chlamydia pneumoniae had a slight higher fatality rate compared to the other group of patients, even if not statistically significant (24.2% vs 21.8%, p=0.63). However, multivariate logistic regression showed that age >65 years was an independent risk factor for death in patients with SARS-CoV-2 infection and seropositive for Mycoplasma and/or Chlamydia pneumoniae (OR=4.02, 95%CI=1.7-11, p=0.003) .

Chlamydia/Mycoplasma pneumoniae positivity by serology (OR=2.2, 95%CI=1.6-3.0, p<0.0001) .

A logistic regression for univariate and multivariate analyses was performed in order to identify risk factors associated with Chlamydia/Mycoplasma infection in SARS-CoV-2 positive patients.

Six categorical variables were identified in univariate logistic regression analysis, namely: male sex, lymphopenia, ALT >50 U/L, PCR>20 mg/L, hyperlipidemia and chronic renal disease (Fig. 1A) .

Only chronic renal disease was demonstrated as independent risk factor based on the multivariate logistic regression model (Fig. 1B) .

To the best of our knowledge, this study was the first in Europe to report a high rate of detection of antibody positivity for these atypical pathogens in SARS-CoV-2 infected patients, with 26% of the 

Co-infections in people with COVID-19: a Systematic review and meta-analysis

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan China

Presenting characteristics, comorbidities, and outcomes of patients coinfected with COVID-19 and Mycoplasma pneumoniae in the USA

Coinfection and other clinical characteristics of COVID-19 in children

COVID-19 and Mycoplasma pneumoniae coinfection

A case of childhood COVID 19 infection with pleural effusion complicated by possible secondary Mycoplasma pneumoniae infection

Mycoplasma infection may complicate the clinical course of SARS-CoV-2 associated Kawasaki-like disease in children

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City

Risk of ruling out severe acute respiratory syndrome by ruling in another diagnosis: variable incidence of atypical bacteria coinfection based on diagnostic assays

We thank all medical and healthcare workers of Spedali Civili's Hospital, Montichiari's Hospital and Gardone Val Trompia's Hospital who are fighting against this pandemic and are directly involved in the care of patients. We also thank all the medical and technical staff of the Microbiology section for the performance of all microbiological tests.